This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
, No Gclids
Disease Info Card
Acquired Partial Lipodystrophy
Information about Acquired Partial Lipodystrophy: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Overview of Acquired Partial Lipodystrophy
Most recent studies have shown that Acquired Partial Lipodystrophy shares some biological mechanisms with atrophy, cardiomyopathies, cardiomyopathy-dilated, diabetes-mellitus, diabetes-mellitus-non-insulin-dependent, dyslipidemias, dystrophy, familial-generalized-lipodystrophy, familial-partial-lipodystrophy, glomerulonephritis, glomerulonephritis-membranoproliferative, hyperlipidemia, hypertrophy, insulin-resistance, kidney-diseases, lipodystrophy, muscular-dystrophy, muscular-dystrophy-emery-dreifuss, obesity.
Among the many pathways, these few ones have gauged particular interests from scientists studying Acquired Partial Lipodystrophy, and have been seen in publications frequently: Aging, Cardiac Conduction, Cell Cycle, Chromatin Organization, Chromatin Remodeling, Complement Activation, Dna Methylation, Dna Replication, Glucose Homeostasis, Glycosylation, Localization, Mitosis, Muscle Atrophy, Muscle Hypertrophy, Pathogenesis, Pigmentation, Reflex, Regeneration, Secretion, Transport
Quite a number of genes have been found to play important roles in Acquired Partial Lipodystrophy, such as ADIPOQ, AGPAT2, AMPD1, BSCL2, C3, C5, CFH, EMD, ERMAP, INS, LEP, LMNA, LMNB2, PPARA, PPARG, SREBF1, ZMPSTE24. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.